Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma

Blood

Volumn 104, Issue 6, 2004, Pages 1624-1630

  Thomas, Deborah A ^a   O'Brien, Susan ^a   Cortes, Jorge ^a   Giles, Francis J ^a   Faderl, Stefan ^a   Verstovsek, Srdan ^a   Ferrajoli, Alessandra ^a   Koller, Charles ^a   Beran, Miloslav ^a   Pierce, Sherry ^a   Ha, Chul S ^a   Cabanillas, Fernando ^a   Keating, Michael J ^a   Kantarjian, Hagop ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ASPARAGINASE; BETA 2 MICROGLOBULIN; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; LACTATE DEHYDROGENASE; METHOTREXATE; MONOCLONAL ANTIBODY; NUCLEOSIDE ANALOG; PREDNISONE; VINCRISTINE;

ACUTE LYMPHOCYTIC LEUKEMIA; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM METASTASIS; CLINICAL ARTICLE; DRUG DOSE REGIMEN; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN TISSUE; ILEUS; IMMUNOPHENOTYPING; KIDNEY DISEASE; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKEMIA REMISSION; LYMPHOBLASTOMA; MAINTENANCE THERAPY; MALE; MEDIASTINUM DISEASE; MEDIASTINUM TUMOR; MYCOSIS; NAUSEA; NEUROMUSCULAR DISEASE; OUTCOMES RESEARCH; PANCREATITIS; PERICARDITIS; PERIPHERAL NEUROPATHY; PNEUMONIA; PRIORITY JOURNAL; PROPHYLAXIS; PYREXIA IDIOPATHICA; RASH; RELAPSE; RISK FACTOR; SEPSIS; SKIN DISEASE; STOMATITIS; T LYMPHOCYTE; TOXIC HEPATITIS; TREATMENT OUTCOME; VOMITING;

EID: 4444268220     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-12-4428     Document Type: Article

References (41)

1. Thomas D, Kantarjian H. Lymphoblastic lymphoma. In: Kantarjian H, Hoelzer D, Larson R, eds. Hematology/Oncology Clinics of North America: Advances in the Treatment of Adult Leukemia, Part II. Vol 15. Philadelphia, PA: W.B. Saunders; 2001;51-95.
2. Coleman CN, Picozzi VJ, Cox RS, et al. Treatment of lymphoblastic lymphoma in adults. J Clin Oncol. 1986;4:1628-1637.
3. Picozzi VJ Jr, Coleman CN. Lymphoblastic lymphoma. Semin Oncol. 1990;17:96-103.
4. Quintanilla-Martinez L, Zukerbert L, Harris NL. Prethymic adult lymphoblastic lymphoma: a clinicopathologic and immunohistochemical analysis. Am J Surg Pathol. 1992;16:1075-1084.
5. The non-Hodgkin's lymphoma pathological classification project: The National Cancer Institute-sponsored study of classifications of non-Hodgkin's lymphomas. Cancer. 1982;49:2112-2135.
6. Streuli RA, Kaneko Y, Variakojis D, et al. Lymphoblastic lymphoma in adults. Cancer. 1981;47:2510-2516.
7. Nathwani BN, Diamond LW, Winberg CD, et al. Lymphoblastic lymphoma: a clinicopathologic study of 95 patients. Cancer. 1981;48:2347-2357.
8. Soslow RA, Baergen RN, Warnke RA. B-lineage lymphoblastic lymphoma is a clinicopathologic entity distinct from other histologically similar aggressive lymphomas with blastic morphology. Cancer. 1999;85:2648-2654.
9. Weiss LM, Bindl FM, Picozzi VJ, et al. Lymphoblastic lymphoma: an immunophenotype study of 26 cases with comparison to T cell acute lymphoblastic leukemia. Blood. 1986;67:474-478.
10. Catovsky D, Goldman JM, Okos A, et al. T-lymphoblastic leukemia: a distinct variant of acute leukemia. Br Med J. 1974;2:643-646.
11. Bouabdallah L, Xerri L, Bardou VJ, et al. Role of induction chemotherapy and bone marrow transplantation in adult lymphoblastic lymphoma: a report on 62 patients from a single center. Ann Oncol. 1998;9:619-625.
12. Morel P, Lepage E, Brice P, et al. Prognosis and treatment of lymphoblastic lymphoma in adults: a report on 80 patients. J Clin Oncol. 1992;10:1078-1085.
13. Slater DE, Mertelsmann R, Koziner B, et al. Lymphoblastic lymphoma in adults. J Clin Oncol. 1986;4:57-67.
14. Zinzani PL, Bendandi M, Visani G, et al. Adult lymphoblastic lymphoma: clinical features and prognostic factors in 53 patients. Leuk Lymphoma. 1996;23:577-582.
15. Bemasconi C, Brusamolino E, Lazzarino M, Morra E, Pagnucco G, Oriandi E. Lymphoblastic lymphoma in adult patients: clinicopathological features and response to intensive multiagent chemotherapy analogous to that used in acute lymphblastic leukemia. Ann Oncol. 1990;1:141-146.
16. Daenen S, van Imhoff GW, Haaxma-Reiche H, et al. Outcome of a hybrid chemotherapy regimen with mediastinal irradiation in leukemic T-lymphoblastic lymphoma [abstract]. Blood. 1995;86:754a.
17. Dekker AW, van't Veer MB, Sizoo W, et al. Intensive post-remission chemotherapy without maintenance therapy in adults with acute lymphoblastic leukemia: Dutch Hemato-Oncology Research Group. J Clin Oncol. 1997;15:476.
18. Kobayashi T, Tobinai K, Shimoyama M, et al. Long-term follow-up results of adult patients with acute lymphocytic leukemia or lymphoblastic lymphoma treated with short-term, alternating noncross resistant chemotherapy: Japan Clinical Oncology Group Study 8702, Lymphoma Study Group. Jpn J Clin Oncol. 1999;29:340-348.
19. Neth O, Seidemann K, Jansen P, et al. Precursor B-cell lymphoblastic lymphoma in childhood and adolescence: clinical features, treatment, and results in trials NHL-BFM 86 and 90. Med Pediatr Oncol. 2000;35:20-27.
20. Kantarjian HM, O'Brien S, Smith TL, et al. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol. 2000;18:547-561.
21. Thomas DA, Cortes J, Giles FJ, et al. Update of the modified hyper-CVAD regimen in newly diagnosed adult acute lymphocytic leukemia (ALL) [abstract]. Blood. 2003;102:880a.
22. Stansfeld AG, Diebold J, Noel H, et al. Updated Kiel classification for lymphomas. Lancet. 1988;1:292-293.
23. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasma: a proposal from the International Lymphoma Study Group. Blood. 1994;84:1361-1392.
24. Kantarjian HM, Smith TL, O'Brien S, et al. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. Ann Intern Med. 1995;122:254-261.
25. Faderi S, Kantarjian HM, Talpaz M, Estrov Z. Clinical significance of cytogenetic abnormalities in adult acute lymphoblastic leukemia. Blood. 1998;91:3995-4019.
26. Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res. 1971;31:1860-1861.
27. Cortes J, O'Brien SM, Pierce S, et al. The value of high-dose systemic chemotherapy and intrathecal therapy for central nervous system prophylaxis in different risk groups of adult acute lymphoblastic leukemia. Blood. 1995;86:2091-2097.
28. Cox DR. Regression models and life tables. J R Stat Soc [B]. 1972;34;187-220.
29. Kaplan EL, Meier P. Non-parametric estimation form incomplete observations. J Am Stat Assoc. 1965;53:457-481.
30. Inhom RC, Aster JC, Roach SA, et al. A syndrome of lymphoblastic lymphoma, eosinophilia, and myeloid hyperplasia/malignancy associated with t(8;13)(p11;q11): description of a distinctive clinicopathologic entity. Blood. 1995;85:1881-1887.
31. Hoelzer D, Gökbuget N, Digel W, et al. Outcome of adult patients with T-lymphoblastic lymphoma treated according to protocols for acute lymphoblastic leukemia. Blood. 2002;99:4379-4385.
32. Murphy SB, Hustu HO. A randomized trial of combined modality therapy of childhood non-Hodgkin's lymphoma. Cancer. 1980;45:630-637.
33. Tubergen DG, Krailo MD, Meadows AT, et al. Comparison of treatment regimens for pediatric lymphoblastic non-Hodgkin's lymphoma: a Childrens Cancer Group study. J Clin Oncol. 1995;13:1368-1376.
34. Retter A, Schrappe M, Ludwig WD, et al. Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma: a BFM group report. Blood. 2000;95:416-421.
35. Kantarjian HM, Walters RS, Keating MJ, et al. Results of the vincristine, doxorubicin, and dexamethasone regimen in adults with standard- and high-risk acute lymphocytic leukemia. J Clin Oncol. 1990;8:994-1004.
36. Dabaja BS, Ha CS, Thomas DA, et al. The role of local radiation therapy for mediastinal disease in adults with T-cell lymphoblastic lymphoma. Cancer. 2002;94:2738-2744.
37. Le Gouill S, Lepretre S, Briere J, et al. Adult lymphoblastic lymphoma: a retrospective analysis of 92 patients under 61 years included in the LNH87/93 trials. Leukemia. 2003;17:2220-2224.
38. Keating MJ, Cazin B, Coutre S, et al. Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed. J Clin Oncol. 2002;20:205-213.
39. Kisor DF, Plunkett W, Kurtzberg J, et al. Pharmacokinetics of nelarabine and 9-beta-D-arabinofuranosyl guanine in pediatric and adult patients during a phase I study of nelarabine for the treatment of refractory hematologic malignancies. J Clin Oncol. 2000;18:995-1003.
40. Thomas D, Kantarjan H, O'Brien S, et al. Outcome with the hyper-CVAD regimen in lymphoblastic lymphoma (LL) [abstract]. Proc Am Soc Clin Oncol. 1999;18:11a.
41. Thomas DA, Cortes J, O'Brien SM, et al. Improved outcome with the hyper-CVAD regimen in lymphoblastic lymphoma [abstract]. Blood 2000;96:833a.